Name | No. | For Patients with | Purpose |
---|---|---|---|
HELP-ER | 22-05 | First platinum sensitive relapsed ovarian cancer |
Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer. Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer. This study aims to improve upon the contemporary AGO score by including additional clinical variables like circulating HE4 and CA125 levels to predict surgical outcome at secondary cytoreduction. |
DSSG Group: Gynaecological
ENGOT-en15/ KEYNOTE-C93-00/ GOG-3064
Name | No. | For Patients with | Purpose |
---|---|---|---|
ENGOT-en15/ KEYNOTE-C93-00/ GOG-3064 | 22-02 | Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting |
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. |
OVHIPEC-2
Name | No. | For Patients with | Purpose |
---|---|---|---|
OVHIPEC-2 | 20-07 | Stage III Epithelial Ovarian Cancer |
The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) |